Clinical Trial Update: A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers [Phase 1]

View source ↗

Summary

Phase 1, single-dose pilot study evaluating radiolabeled amatuximab (MORAb-009) in mesothelin-overexpressing cancers has completed. The study included mesotheli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mesothelioma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer

Drugs mentioned

• Amatuximab (MORAb-009) (amatuximab)

Snippet

Sponsor: Morphotek | Conditions: Mesothelioma, Pancreatic Cancer | Phase 1 | Status: COMPLETED